Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
HER2
KRAS
MET
NTRK
PIK3CA
RET
non-small cell lung cancer
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Mar 2021
05 Mar 2021
Historique:
received:
14
02
2021
revised:
28
02
2021
accepted:
01
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
23
4
2021
Statut:
epublish
Résumé
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros oncogene 1 (ROS1), and V-raf murine sarcoma viral oncogene homolog B (BRAF) have been approved and are currently used in clinical practice. However, other promising molecular drivers are rapidly emerging as therapeutic targets. This review aims to cover the molecular alterations with a potential clinical impact in NSCLC, including amplifications or mutations of the mesenchymal-epithelial transition factor (MET), fusions of rearranged during transfection (RET), rearrangements of the neurotrophic tyrosine kinase (NTRK) genes, mutations of the Kirsten rat sarcoma viral oncogene (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), as well as amplifications or mutations of human epidermal growth factor receptor 2 (HER2). Additionally, we summarized the current status of targeted agents under investigation for such alterations. This revision of the current literature on emerging molecular targets is needed as the evolving knowledge on novel actionable oncogenic drivers and targeted agents is expected to increase the proportion of patients who will benefit from tailored therapeutic approaches.
Identifiants
pubmed: 33807876
pii: ijms22052625
doi: 10.3390/ijms22052625
pmc: PMC7961376
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Neoplasm Proteins
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
PLoS One. 2014 Feb 12;9(2):e88291
pubmed: 24533074
Nat Med. 2020 Jan;26(1):47-51
pubmed: 31932802
Ann Oncol. 2013 Sep;24(9):2371-6
pubmed: 23723294
J Thorac Oncol. 2014 Jul;9(7):1031-1035
pubmed: 24926548
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
Ann Oncol. 2001;12 Suppl 1:S97-100
pubmed: 11521731
Clin Cancer Res. 2012 Sep 15;18(18):4910-8
pubmed: 22761469
Cancer Cell. 2010 Jul 13;18(1):63-73
pubmed: 20609353
Genes Cancer. 2012 Jul;3(7-8):459-66
pubmed: 23264846
J Neurosci. 1999 Nov 1;19(21):9322-31
pubmed: 10531437
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Lung Cancer. 2020 Dec;150:21-25
pubmed: 33045465
Int J Clin Oncol. 2020 Aug;25(8):1450-1458
pubmed: 32440811
Onco Targets Ther. 2020 Mar 25;13:2491-2510
pubmed: 32273721
J Thorac Oncol. 2017 Aug;12(8):1233-1246
pubmed: 28502721
Target Oncol. 2018 Oct;13(5):545-556
pubmed: 30276762
J Thorac Oncol. 2019 Jun;14(6):1086-1094
pubmed: 30825613
JCO Precis Oncol. 2018;2018:
pubmed: 30215037
Lab Invest. 2017 Nov;97(11):1332-1342
pubmed: 28604655
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
Cancer. 2020 Nov 15;126(22):4826-4837
pubmed: 32888330
Clin Cancer Res. 2014 Jan 1;20(1):233-45
pubmed: 24166903
Curr Oncol Rep. 2020 Apr 16;22(5):48
pubmed: 32296961
J Thorac Oncol. 2016 Mar;11(3):414-9
pubmed: 26723242
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905960
Int J Mol Sci. 2016 Dec 14;17(12):
pubmed: 27983617
J Thorac Oncol. 2020 Apr;15(4):628-636
pubmed: 31945494
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Oncology. 2002;63 Suppl 1:33-8
pubmed: 12422053
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Mol Cancer Ther. 2013 Feb;12(2):220-9
pubmed: 23371856
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Thorac Oncol. 2014 May;9(5):622-30
pubmed: 24722152
J Thorac Oncol. 2015 Sep;10(9):1319-1327
pubmed: 26098748
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Lung Cancer. 2016 Nov;101:16-21
pubmed: 27794403
Crit Rev Oncol Hematol. 2020 Dec;156:103118
pubmed: 33038627
Lung Cancer. 2021 Jan;151:53-59
pubmed: 33310622
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
Neuron. 1998 Dec;21(6):1291-302
pubmed: 9883723
Oncotarget. 2015 Jan 20;6(2):1315-26
pubmed: 25473901
Lancet Oncol. 2016 Dec;17(12):1653-1660
pubmed: 27825636
Thorac Cancer. 2020 Jun;11(6):1512-1521
pubmed: 32291971
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
Cancer Treat Rev. 2020 Jul;87:102022
pubmed: 32334240
J Thorac Oncol. 2014 Mar;9(3):316-23
pubmed: 24496004
Curr Treat Options Oncol. 2020 Apr 18;21(4):33
pubmed: 32306194
N Engl J Med. 1990 Aug 30;323(9):561-5
pubmed: 2199829
Clin Lung Cancer. 2021 Jan;22(1):1-5
pubmed: 33272813
Crit Rev Oncol Hematol. 2021 Jan;157:103194
pubmed: 33316418
Expert Opin Pharmacother. 2020 Nov;21(16):1935-1942
pubmed: 32736487
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Cancer Manag Res. 2020 Dec 08;12:12593-12602
pubmed: 33324104
Thorac Cancer. 2020 Mar;11(3):511-518
pubmed: 31989769
Clin Cancer Res. 2016 Jun 15;22(12):3048-56
pubmed: 26847053
Crit Rev Oncol Hematol. 2020 Dec;156:103119
pubmed: 33053439
Int J Mol Sci. 2020 Sep 26;21(19):
pubmed: 32993133
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
JCO Precis Oncol. 2019;3:
pubmed: 31157314
Ann Oncol. 2019 Mar 1;30(3):447-455
pubmed: 30596880
Clin Cancer Res. 2019 Dec 15;25(24):7312-7319
pubmed: 31416808
J Mol Diagn. 2017 Mar;19(2):244-254
pubmed: 28027945
Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252
pubmed: 30050303
Lung Cancer. 2019 Jul;133:96-102
pubmed: 31200835
Br J Cancer. 2014 Mar 18;110(6):1571-8
pubmed: 24504365
Eur J Cancer. 2017 Nov;86:186-196
pubmed: 28992562
Biomed Res Int. 2020 Aug 17;2020:3608241
pubmed: 32908885
Lung Cancer. 2015 Jan;87(1):14-22
pubmed: 25468202
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55
pubmed: 32760015
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
BMC Cancer. 2015 Mar 23;15:171
pubmed: 25881079
Mol Med Rep. 2018 Aug;18(2):2191-2197
pubmed: 29956783
Lung Cancer. 2019 Dec;138:124-130
pubmed: 31710864
Lung Cancer. 2016 Mar;93:43-6
pubmed: 26898613
Pharmaceuticals (Basel). 2012 Nov 20;5(11):1236-64
pubmed: 24281308
Curr Oncol Rep. 2021 Jan 2;23(1):10
pubmed: 33387080
Lung Cancer. 2020 Mar;141:21-31
pubmed: 31931443
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Expert Rev Anticancer Ther. 2020 May;20(5):333-341
pubmed: 32223357
Oncologist. 2015 Mar;20(3):245-6
pubmed: 25669662
Br J Cancer. 2018 Dec;119(12):1471-1476
pubmed: 30425349
J Thorac Oncol. 2019 Oct;14(10):1839-1846
pubmed: 31158500
Nature. 1996 Dec 5;384(6608):467-70
pubmed: 8945474
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Ann Oncol. 2019 Dec 1;30(12):1985-1991
pubmed: 31584608
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
Cancers (Basel). 2019 Dec 17;11(12):
pubmed: 31861060
Lung Cancer. 2013 Oct;82(1):44-50
pubmed: 23932363
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):577-582
pubmed: 31659111
Lung Cancer Manag. 2014 Jan 1;3(1):67-75
pubmed: 25342981
J Thorac Oncol. 2018 Feb;13(2):273-279
pubmed: 29313813
J Clin Oncol. 2012 Dec 10;30(35):4352-9
pubmed: 23150706
J Clin Med. 2020 Jun 19;9(6):
pubmed: 32575417
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
Mol Cancer. 2018 Feb 19;17(1):33
pubmed: 29455666
Oncotarget. 2017 Jul 18;8(29):48248-48252
pubmed: 28525386
J Thorac Oncol. 2016 Jan;11(1):122-7
pubmed: 26762747
Cancer Cell. 2020 Mar 16;37(3):420
pubmed: 32183953
Lancet Respir Med. 2017 Jan;5(1):42-50
pubmed: 27825616
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Ann Oncol. 2017 Dec 1;28(12):3070-3075
pubmed: 29045504
Clin Cancer Res. 2020 Jun 1;26(11):2535-2545
pubmed: 32086345
Onco Targets Ther. 2020 Jun 17;13:5691-5706
pubmed: 32606781
Curr Biol. 2005 Jul 26;15(14):R563-74
pubmed: 16051167
Data Brief. 2016 Sep 24;9:689-695
pubmed: 27790634
Mol Cancer. 2014 Jul 21;13:176
pubmed: 25047660
Front Oncol. 2020 Oct 26;10:578756
pubmed: 33194700
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Lung Cancer. 2012 Oct;78(1):100-6
pubmed: 22906736
Nat Med. 2012 Mar 06;18(3):349-51
pubmed: 22395697
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Clin Lung Cancer. 2014 Mar;15(2):159-65
pubmed: 24370118